Skip to content

Food and Drugs Act

R.S.C., 1985, c. F-27

In forceCurrent to September 30, 2026 History

Loading…

Schedules

SCHEDULE A(Section 2.4)

PART 1

Things that Fall Within Definition “Food” in Section 2

ItemDescription
 
 

PART 2

Things that Fall Within Definition “Drug” in Section 2

ItemDescription
 
 

PART 3

Things that Fall Within Definition “Cosmetic” in Section 2

ItemDescription
 
 

PART 4

Things that Fall Within Definition “Device” in Section 2

ItemDescription
 
 
  • 2019, c. 29, s. 178
.

SCHEDULE A.1(Section 3)

  • Acute alcoholism

    Alcoolisme aigu

  • Acute anxiety state

    État anxieux aigu

  • Acute infectious respiratory syndromes

    Syndromes respiratoires infectieux aigus

  • Acute, inflammatory and debilitating arthritis

    Arthrite aiguë, inflammatoire et débilitante

  • Acute psychotic conditions

    Troubles psychotiques aigus

  • Addiction (except nicotine addiction)

    Dépendance (sauf la dépendance à la nicotine)

  • Appendicitis

    Appendicite

  • Arteriosclerosis

    Artériosclérose

  • Asthma

    Asthme

  • Cancer

    Cancer

  • Congestive heart failure

    Insuffisance cardiaque congestive

  • Convulsions

    Convulsions

  • Dementia

    Démence

  • Depression

    Dépression

  • Diabetes

    Diabète

  • Gangrene

    Gangrène

  • Glaucoma

    Glaucome

  • Haematologic bleeding disorders

    Affections hématologiques hémorragiques

  • Hepatitis

    Hépatite

  • Hypertension

    Hypertension

  • Nausea and vomiting of pregnancy

    Nausées et vomissements de la grossesse

  • Obesity

    Obésité

  • Rheumatic fever

    Rhumatisme articulaire aigu

  • Septicemia

    Septicémie

  • Sexually transmitted diseases

    Maladies transmises sexuellement

  • Strangulated hernia

    Hernie étranglée

  • Thrombotic and Embolic disorders

    Maladies thrombotiques et embolies

  • Thyroid disease

    Glande thyroïdienne (affections)

  • Ulcer of the gastro-intestinal tract

    Ulcères des voies gastro-intestinales

  • R.S., 1985, c. F-27, Sch. A
  • SOR/88-252
  • SOR/89-503
  • SOR/90-655
  • SOR/92-198
  • SOR/94-287
  • SOR/99-413, 414
  • SOR/2007-289, ss. 1, 2
  • 2019, c. 29, s. 177
.

SCHEDULE B(Section 10)

The most recent editions, including all errata, supplements, revisions and addenda, of the following standards:

Column IColumn II
ItemNameAbbreviation
1European Pharmacopoeia(Ph.Eur.)
2Pharmacopée française(Ph.F.)
3Pharmacopoeia Internationalis(Ph.I.)
4The British Pharmacopoeia(B.P.)
5The Canadian Formulary(C.F.)
6The National Formulary(N.F.)
7The Pharmaceutical Codex: Principles and Practices of Pharmaceuticals
8The United States Pharmacopoeia(U.S.P.)
  • R.S., 1985, c. F-27, Sch. B
  • SOR/85-276
  • SOR/89-315
  • SOR/90-160
  • SOR/94-288
  • SOR/95-530, s. 2
  • SOR/96-96
.

SCHEDULE C(Section 12)

  • Drugs, other than radionuclides, sold or represented for use in the preparation of radiopharmaceuticals

    Drogues...

  • Radiopharmaceuticals

    Produits pharmaceutiques radioactifs

  • R.S., c. F-27, Sch. C
  • SI/72-44
  • SI/76-1
  • SOR/79-237
  • SOR/81-195, 332
  • SOR/82-769
.

SCHEDULE D(Section 12)

  • Allergenic substances used for the treatment or diagnosis of allergic or immunological diseases

    Substances...

  • Anterior pituitary extracts

    Extraits hypophysaires (lobe antérieur)

  • Aprotinin

    Aprotinine

  • Cholecystokinin

    Cholécystokinine

  • Drugs obtained by recombinant DNA procedures

    Drogues obtenues...

  • Drugs, other than antibiotics, prepared from micro-organisms

    Drogues, sauf...

  • Drugs that are or are made from blood

    Drogue qui est...

  • Glucagon

    Glucagon

  • Gonadotrophins

    Gonadotrophines

  • Immunizing agents

    Agents immunisants

  • Insulin

    Insuline

  • Interferon

    Interféron

  • Monoclonal antibodies, their conjugates and derivatives

    Anticorps monoclonaux et leurs dérivés et conjugués

  • Secretin

    Sécrétine

  • Snake Venom

    Venin de serpent

  • Urokinase

    Urokinase

  • R.S., 1985, c. F-27, Sch. D
  • SOR/85-715, s. 1
  • SOR/89-177
  • SOR/93-64
  • SOR/97-560
  • SOR/2007-120
  • SOR/2013-180
.

SCHEDULE E(Section 13)

[There are no items in this Schedule.]

  • R.S., c. F-27, Sch. E
  • SOR/77-824
  • SOR/82-769
.

SCHEDULE F(Section 15)

[There are no items in this Schedule of the FOOD AND DRUGS ACT.]

  • R.S., c. F-27, Sch. F
  • SOR/84-566
.

SCHEDULE G(Sections 2 and 21.91)

ItemDescription
 
 
  • R.S., 1985, c. F-27, Sch. G
  • SOR/92‑387
  • 1996, c. 19, s. 82
  • 2019, c. 29, s. 179
.

SCHEDULE H

[Repealed, 1996, c. 19, s. 82]

RELATED PROVISIONS

  • — R.S., 1985, c. 27 (1st Supp.), s. 208

    • Writs of Assistance

      208 Nothing in sections 190, 195, 199 and 200 of this Act shall be construed as rendering invalid or inadmissible in any proceedings any evidence obtained by the exercise of a writ of assistance prior to the coming into force of those sections.

  • — 1997, c. 6, s. 66(2)

    • Transitional
      • 66 (2) For greater certainty, the two year limitation period provided for in subsection 32(1) of the Act, as amended by subsection (1), only applies in respect of offences committed after the coming into force of that subsection.

  • — 2005, c. 42, s. 4

    • Deeming provision

      4 A Notice of Interim Marketing Author­ization that is issued under the Food and Drug Regulations before the day on which this section comes into force, in respect of any matter referred to in subsection 30.2(2) of the Food and Drugs Act, as enacted by section 3 of this Act, and that is in effect on the day on which this section comes into force, is deemed to be an interim marketing authorization issued under subsection 30.2(1) of that Act.

  • — 2005, c. 42, s. 5(1)

    • Pest control products
      • 5 (1) The maximum residue limit established for an agricultural chemical and its derivatives under the Food and Drug Regulations, as those regulations read immediately before the coming into force of this subsection, is deemed, if the agricultural chemical is a pest control product as defined in subsection 2(1) of the Pest Control Products Act, chapter 28 of the Statutes of Canada, 2002, to have been specified by the Minister under section 9 or 10 of that Act as the maximum residue limit for that agricultural chemical and its derivatives.

  • — 2012, c. 19, s. 417

    • Interim marketing authorization
      • 417 (1) An interim marketing authorization that is issued under subsection 30.2(1) of the Food and Drugs Act and in effect immediately before the day on which section 416 comes into force continues to have effect until the earliest of

        • (a) the day on which the Minister of Health publishes a notice cancelling the interim marketing authorization in the Canada Gazette;

        • (b) the day on which a marketing authorization — or any part of it — that is issued under subsection 30.3(1) of the Food and Drugs Act, as enacted by section 416, has the same effect as the interim marketing authorization; and

        • (c) two years after the day on which the interim marketing authorization is published in the Canada Gazette.

      • Exemption from Statutory Instruments Act

        (2) A notice cancelling an interim marketing authorization is exempt from sections 3, 5 and 11 of the Statutory Instruments Act.

  • — 2014, c. 24, s. 13

    • Therapeutic product authorizations

      13 The definition therapeutic product authorization, as enacted by subsection 2(3), applies to authorizations — including licences and suspended authorizations or licences — that were issued before the day on which this section comes into force and that authorize, as the case may be, the import, sale, advertisement, manufacture, preparation, preservation, packaging, labelling, storage or testing of a therapeutic product.

  • — 2019, c. 29, s. 180

    • Clinical trials — certain drugs

      180 A person that, immediately before the coming into force of section 166, is authorized under Division 5 of Part C of the Food and Drug Regulations to sell or import a drug for the purposes of a clinical trial is deemed to be the holder, in respect of that drug, of an authorization referred to in section 3.1 of the Food and Drugs Act, as enacted by that section 166.

  • — 2019, c. 29, s. 181

    • Studies — positron-emitting radiopharmaceuticals

      181 A person that, immediately before the coming into force of section 166, is authorized under Division 3 of Part C of the Food and Drug Regulations to sell or import a positron-emitting radiopharmaceutical for the purposes of a study is deemed to be the holder, in respect of that positron-emitting radiopharmaceutical, of an authorization referred to in section 3.1 of the Food and Drugs Act, as enacted by that section 166.

  • — 2019, c. 29, s. 182

    • Clinical trials — natural health products

      182 A person that, immediately before the coming into force of section 166, is authorized under Part 4 of the Natural Health Products Regulations to sell or import a natural health product for the purposes of a clinical trial is deemed to be the holder, in respect of that natural health product, of an authorization referred to in section 3.1 of the Food and Drugs Act, as enacted by that section 166.

  • — 2019, c. 29, s. 183

    • Investigational testing — certain medical devices

      183 A person that, immediately before the coming into force of section 166, is authorized under Part 3 of the Medical Devices Regulations to sell or import a Class II, III or IV medical device for investigational testing is deemed to be the holder, in respect of the device, of an authorization referred to in section 3.1 of the Food and Drugs Act, as enacted by that section 166.

  • — 2022, c. 17, s. 76

    • Clarification — immediate application

      76 For greater certainty, but subject to sections 77 and 78, the amendments made by this Act also apply with respect to proceedings that are ongoing on the day on which this Act comes into force.

  • — 2022, c. 17, par. 77(2)(a)

    • Certain applications for warrants
      • 77 (2) Each of the following provisions, as it read immediately before the day on which this Act comes into force, continues to apply with respect to an application made for a warrant under the provision if the application is submitted, and no decision has been made in respect of the application, before that day:

        • (a) subsection 23(12) of the Food and Drugs Act;

  • — 2022, c. 17, s. 78.1

    • Impact of remote proceedings
      • 78.1 (1) The Minister of Justice must, no later than three years after the day on which this Act receives royal assent, initiate one or more independent reviews on the use of remote proceedings in criminal justice matters that must include an assessment of whether remote proceedings

        • (a) enhance, preserve or adversely affect access to justice;

        • (b) maintain fundamental principles of the administration of justice; and

        • (c) adequately address the rights and obligations of participants in the criminal justice system, including accused persons.

      • Report

        (2) The Minister of Justice must, no later than five years after the day on which a review is initiated, cause a report on the review — including any findings or recommendations resulting from it — to be laid before each House of Parliament.

  • — 2022, c. 17, s. 78.2

    • Review by committee
      • 78.2 (1) At the start of the fifth year after the day on which this Act receives royal assent, the provisions enacted or amended by this Act are to be referred to a committee of the Senate and a committee of the House of Commons that may be designated or established for the purpose of reviewing the provisions.

      • Report

        (2) The committees to which the provisions are referred are to review them and the use of remote proceedings in criminal justice matters and submit reports to the Houses of Parliament of which they are committees, including statements setting out any changes to the provisions that they recommend.

  • — 2023, c. 26, s. 503

    • Authorizations and licences

      503 The definition therapeutic product authorization in section 2 of the Food and Drugs Act also includes

      • (a) an authorization, including a licence, that was issued, before the day on which this section comes into force, under the regulations made under that Act and that authorizes, as the case may be, the import, sale, manufacture, packaging or labelling of a natural health product, within the meaning of the Natural Health Products Regulations as those Regulations read immediately before that day; or

      • (b) an authorization, including a licence, that would fall within paragraph (a) if the authorization were not suspended.

  • — 2024, c. 17, s. 332

    • Marketing authorizations

      332 Marketing authorizations issued under section 30.2 or 30.3 of the Food and Drugs Act, as those sections read immediately before the day on which section 330 comes into force, that have not been repealed before that day are deemed to be made under subsection 30.05(1) of that Act.

AMENDMENTS NOT IN FORCE

  • — 2023, c. 12, s. 64

    • 64 The Food and Drugs Act is amended by adding the following after section 11:

      • Risk to environment

        11.1 It is prohibited for a person to sell, or to manufacture, prepare, preserve, package or store for sale, any drug that contains a prescribed substance, unless the Minister has conducted an assessment, in accordance with the regulations made under paragraph 30(1)(l.1), of the risk to the environment presented by the substance.

  • — 2023, c. 12, s. 67

      • 67 (1) [In force]

      • (2) Subsection 30(1) of the Act is amended by adding the following after paragraph (a.01):

        • (a.02) prescribing the substances that are subject to an assessment under section 11.1;

      • (3) and (4) [In force]

      • 1999, c. 33, s. 347

        (5) Paragraph 30(1)(l.1) of the Act is replaced by the following:

        • (l.1) respecting the assessment of the risk to the environment or human life and health of the release into the environment of any food, drug, cosmetic or device;

        • (l.2) respecting, for the purpose of managing risks to the environment identified as part of an assessment under this Act, measures in respect of selling or importing, manufacturing, preparing, preserving, packaging or storing for sale any food, drug, cosmetic or device;

        • (l.3) authorizing the Minister to waive any requirement respecting the assessment under this Act of the risk to the environment presented by a food, drug, cosmetic or device;

      • (6) Section 30 of the Act is amended by adding the following after subsection (1):

        • Relevant factor

          (1.01) Before recommending to the Governor in Council that a regulation be made under paragraph (1)(a.02), the Minister must take into account the degree of uncertainty respecting the risks to the environment associated with the use of a substance as an ingredient in a drug, including its release into the environment.

      • (7) to (9) [In force]

  • — 2023, c. 26, s. 501(2)

  • — 2023, c. 26, s. 502(2)

  • — 2024, c. 17, s. 327

      • 327 (1) Section 30.05 of the Act is amended by adding the following after subsection (1):

        • Exemption — person

          (1.1) Subject to subsection (2) and any regulations made under paragraph 30(1)(j.1), the Minister may, by order, on any conditions that the Minister considers necessary, exempt a person — or any food, therapeutic product or activity, or any class of foods, therapeutic products or activities, in relation to a person — from the application of all or any of the provisions of Part I, section 37 or the regulations. The order cannot relate to cosmetics.

      • (2) The portion of subsection 30.05(2) of the Act before paragraph (a) is replaced by the following:

        • Preconditions

          (2) The Minister may make an order under subsection (1) or (1.1) only if the Minister believes on reasonable grounds that

      • (3) Section 30.05 of the Act is amended by adding the following after subsection (3):

        • Statutory Instruments Act

          (4) An order made under subsection (1.1) that applies to only one person is not a statutory instrument within the meaning of the Statutory Instruments Act.

        • Availability — person-specific orders

          (5) The Minister must ensure that any order made under subsection (1.1) is publicly available but may exclude personal information and confidential business information from the order.

Unofficial reproduction of the consolidated text published by the Department of Justice Canada, permitted by the Reproduction of Federal Law Order. Only the official text is authoritative.